About Event

What’s the Focus of This Year’s Summit?

The 4th Neuroimmunology Drug Development Summit is the unmissable, industry forum exclusively focused on drug discovery and development targeting neuroimmunological mechanisms. Translate key technological, cellular and target insights in neuroinflammation into clinically effective candidates; and connect in person with over 100 colleagues prioritizing research and drug development to troubleshoot and benchmark latest research on the neuropathological and neuroprotective effects of inflammation in the CNS.

What Can You Expect?

Untitled design (1)

Delve into the role of genetics in neuroinflammation and neurodegenerative disease by navigating genetic risk factors associated with neuroinflammation that may predispose neurodegeneration alongside Eisai, MIT and Vir Biotechnology

Untitled design (1)

Examine the implications of the gut-brain axis in neuroinflammation with the help of BioCortex to understand how microglia are monitored using the gut-brain axis to advise therapeutic development

Untitled design (1)

Discover emerging animal model practices increasing the translatability and streamlining of models with Takeda Pharmaceuticals and The University of Florida

Untitled design (1)

Learn about specific targets for neuroinflammation to develop drugs for neurodegenerative diseases from key stakeholders from Lundbeck, Talisman Therapeutics and Elixiron Immunotherapeutics discussing the successes and pitfalls in their clinical research into inflammatory targets

Untitled design (1)

Understand the influence of the peripheral immune system and astrocytes in neuroinflammation alongside Biogen, Takeda Pharmaceuticals, The Harvard Medical School and Sanford Burnham Prebys Medical Discovery Unit and discuss the potential avenues for developing neuroimmunological therapeutics

Untitled design (1)

Investigate neuroinflammation implications in neuropsychiatric conditions by examining genetics associated with neuropsychiatric risk factors with Vir Biotechnology, and discussing targets for neuroinflammation in neuropsychiaty with Lundbeck and Takeda Pharmaceuticals

Past Attendees Include:

26225 Favicon (3)
Janssen_Pharmaceuticals_logo.svg (002)
26225 Favicon (4)
26225 Favicon (5)
acadia (002)
1200px-Biogen_Idec_logo (002)
annexon (002)
bms_logo_TM (002)
26225 Favicon
EMD Serono
Biogen
Denali
Roche
Eisai
Alector
Takeda
26225 Favicon (6)
Merck_Logo (002)
Otsuka_Holdings_logo (002)
MicrosoftTeams-image (2)